|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
It appears that the decreased levels of CTRP3 and especially CTRP13 were associated with increased risk of T2DM and CAD.
|
28033351 |
2016 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
It appears that the decreased levels of CTRP3 and especially CTRP13 were associated with increased risk of T2DM and CAD.
|
28033351 |
2016 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: Irrespective of obesity.
|
30540803 |
2018 |
|
myeloblastosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mutation of K100 significantly reduces the affinity of MoCdc5-DBD to a Cdc5-binding element but not to a conventional myeloblastosis (Myb) domain-binding element, suggesting that K100 is a key residue of the high binding affinity to Cdc5-binding element.
|
31652438 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our aims were to examine whether the plasma levels of CTRP13 are (a) increased in patients with NAFLD; (b) associated with metabolic dysregulation, obesity, liver enzymes, and dyslipidemia; and (c) associated with putative symptoms of NAFLD.
|
30247335 |
2019 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Our aims were to examine whether the plasma levels of CTRP13 are (a) increased in patients with NAFLD; (b) associated with metabolic dysregulation, obesity, liver enzymes, and dyslipidemia; and (c) associated with putative symptoms of NAFLD.
|
30247335 |
2019 |
|
Dyslipidemias
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Our aims were to examine whether the plasma levels of CTRP13 are (a) increased in patients with NAFLD; (b) associated with metabolic dysregulation, obesity, liver enzymes, and dyslipidemia; and (c) associated with putative symptoms of NAFLD.
|
30247335 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The proangiogenic activity of C1ql1/Ctrp14 and C1ql4/Ctrp11 provides novel insights into the new opportunities for therapeutic intervention by targeting C1QLs in tumorigenesis, tissue regeneration, and recovery of ischemic heart disease.
|
27734226 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate a novel regulatory mechanism by which C1ql3/BAI3 signaling causes an impairment of insulin secretion from β-cells, possibly contributing to the progression of type 2 diabetes in obesity.
|
30228187 |
2018 |
|
Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, these results suggest that CTRP13 preserves endothelial function in diabetic mice by regulating GCH1/BH4 axis-dependent eNOS coupling, suggesting the therapeutic potential of CTRP13 against diabetic vasculopathy.
|
31676569 |
2020 |
|
Kidney Failure, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that the serum CTRP13 levels were decreased in patients and rats with CRF and were negatively associated with calcium deposition in the abdominal aorta.
|
31145871 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
We sought to investigate circulating CTRP1, CTRP9, CTRP12 and CTRP13 concentrations in persons with type 2 diabetes mellitus (T2DM), with age and BMI matched controls, and to examine the effects of a 2 hour 75g oral glucose tolerance test (OGTT) on serum CTRP1, CTRP9, CTRP12 and CTRP13 levels in persons with T2DM.
|
28207876 |
2017 |